Literature DB >> 35416772

Protection of nascent DNA at stalled replication forks is mediated by phosphorylation of RIF1 intrinsically disordered region.

Sandhya Balasubramanian1,2, Matteo Andreani1,2, Júlia Goncalves Andrade1, Tannishtha Saha1,2, Devakumar Sundaravinayagam1, Javier Garzón3, Wenzhu Zhang4, Oliver Popp5, Shin-Ichiro Hiraga3, Ali Rahjouei1, Daniel B Rosen6, Philipp Mertins5, Brian T Chait4, Anne D Donaldson3, Michela Di Virgilio1,7.   

Abstract

RIF1 is a multifunctional protein that plays key roles in the regulation of DNA processing. During repair of DNA double-strand breaks (DSBs), RIF1 functions in the 53BP1-Shieldin pathway that inhibits resection of DNA ends to modulate the cellular decision on which repair pathway to engage. Under conditions of replication stress, RIF1 protects nascent DNA at stalled replication forks from degradation by the DNA2 nuclease. How these RIF1 activities are regulated at the post-translational level has not yet been elucidated. Here, we identified a cluster of conserved ATM/ATR consensus SQ motifs within the intrinsically disordered region (IDR) of mouse RIF1 that are phosphorylated in proliferating B lymphocytes. We found that phosphorylation of the conserved IDR SQ cluster is dispensable for the inhibition of DSB resection by RIF1, but is essential to counteract DNA2-dependent degradation of nascent DNA at stalled replication forks. Therefore, our study identifies a key molecular feature that enables the genome-protective function of RIF1 during DNA replication stress.
© 2022, Balasubramanian et al.

Entities:  

Keywords:  DNA replication fork protection; DSB resection inhibition; RIF1; SQ motifs; cancer biology; genetics; genomics; intrinsically disordered region; mouse

Mesh:

Substances:

Year:  2022        PMID: 35416772      PMCID: PMC9007588          DOI: 10.7554/eLife.75047

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.713


  75 in total

1.  DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes.

Authors:  Ofir Hakim; Wolfgang Resch; Arito Yamane; Isaac Klein; Kyong-Rim Kieffer-Kwon; Mila Jankovic; Thiago Oliveira; Anne Bothmer; Ty C Voss; Camilo Ansarah-Sobrinho; Ewy Mathe; Genqing Liang; Jesse Cobell; Hirotaka Nakahashi; Davide F Robbiani; Andre Nussenzweig; Gordon L Hager; Michel C Nussenzweig; Rafael Casellas
Journal:  Nature       Date:  2012-02-07       Impact factor: 49.962

2.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.

Authors:  X Xu; W Qiao; S P Linke; L Cao; W M Li; P A Furth; C C Harris; C X Deng
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

Review 3.  ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.

Authors:  Andrew N Blackford; Stephen P Jackson
Journal:  Mol Cell       Date:  2017-06-15       Impact factor: 17.970

4.  Rif1 phosphorylation site analysis in telomere length regulation and the response to damaged telomeres.

Authors:  Jinyu Wang; Haitao Zhang; Mohammed Al Shibar; Belinda Willard; Alo Ray; Kurt W Runge
Journal:  DNA Repair (Amst)       Date:  2018-03-07

5.  A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.

Authors:  Liu Cao; Xioaling Xu; Samuel F Bunting; Jie Liu; Rui-Hong Wang; Longyue L Cao; J Julie Wu; Tie-Nan Peng; Junjie Chen; Andre Nussenzweig; Chu-Xia Deng; Toren Finkel
Journal:  Mol Cell       Date:  2009-08-28       Impact factor: 17.970

6.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.

Authors:  X Xu; K U Wagner; D Larson; Z Weaver; C Li; T Ried; L Hennighausen; A Wynshaw-Boris; C X Deng
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

7.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Authors:  J Ross Chapman; Inger Brandsma; Guotai Xu; Jingsong Yuan; Martin Mistrik; Peter Bouwman; Jirina Bartkova; Ewa Gogola; Daniël Warmerdam; Marco Barazas; Janneke E Jaspers; Kenji Watanabe; Mark Pieterse; Ariena Kersbergen; Wendy Sol; Patrick H N Celie; Philip C Schouten; Bram van den Broek; Ahmed Salman; Marja Nieuwland; Iris de Rink; Jorma de Ronde; Kees Jalink; Simon J Boulton; Junjie Chen; Dik C van Gent; Jiri Bartek; Jos Jonkers; Piet Borst; Sven Rottenberg
Journal:  Nature       Date:  2015-03-23       Impact factor: 49.962

Review 8.  The Cell Killing Mechanisms of Hydroxyurea.

Authors:  Amanpreet Singh; Yong-Jie Xu
Journal:  Genes (Basel)       Date:  2016-11-17       Impact factor: 4.096

9.  Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells.

Authors:  S Kumar; X Peng; J Daley; L Yang; J Shen; N Nguyen; G Bae; H Niu; Y Peng; H-J Hsieh; L Wang; C Rao; C C Stephan; P Sung; G Ira; G Peng
Journal:  Oncogenesis       Date:  2017-04-17       Impact factor: 7.485

10.  Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.

Authors:  Ting-Wei Will Chiang; Chloe Lescale; Inge de Krijger; Harveer Dev; Alistair G Martin; Domenic Pilger; Julia Coates; Matylda Sczaniecka-Clift; Wenming Wei; Matthias Ostermaier; Mareike Herzog; Jonathan Lam; Abigail Shea; Mukerrem Demir; Qian Wu; Fengtang Yang; Beiyuan Fu; Zhongwu Lai; Gabriel Balmus; Rimma Belotserkovskaya; Violeta Serra; Mark J O'Connor; Alejandra Bruna; Petra Beli; Luca Pellegrini; Carlos Caldas; Ludovic Deriano; Jacqueline J L Jacobs; Yaron Galanty; Stephen P Jackson
Journal:  Nat Cell Biol       Date:  2018-07-18       Impact factor: 28.824

View more
  2 in total

Review 1.  DDK: The Outsourced Kinase of Chromosome Maintenance.

Authors:  Peter J Gillespie; J Julian Blow
Journal:  Biology (Basel)       Date:  2022-06-07

2.  MAD2L2 promotes replication fork protection and recovery in a shieldin-independent and REV3L-dependent manner.

Authors:  Inés Paniagua; Zainab Tayeh; Mattia Falcone; Santiago Hernández Pérez; Aurora Cerutti; Jacqueline J L Jacobs
Journal:  Nat Commun       Date:  2022-09-08       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.